GEORGE C. GRIFFITH, M.D., F.A.C.P.; SIM P. DIMITROFF, M.D., F.A.C.P.; M. C. THORNER, M.D., F.A.C.P.
The most widely studied, recently introduced oral mercurial diuretic has been chlormerodrin (3-chloromercuri-2-methoxypropylurea), registered under the name of Neohydrin.2 The indications for and limitations of oral organomercurial diuretics in the treatment of chronic congestive heart failure have been reported.1
Since Neohydrin is a relatively new medication, its effects after prolonged usage have received limited notice.2 It is the purpose of this study to evaluate its degree of effectiveness during a period of time of from eight to 65 months. In addition, due to the widespread belief that the principal toxicity of organomercurial diuretics appears in the kidney, especial attention was
GRIFFITH GC, DIMITROFF SP, THORNER MC. TREATMENT OF CHRONIC CONGESTIVE HEART FAILURE WITH NEOHYDRIN FOR FROM EIGHT TO 65 MONTHS12. Ann Intern Med. ;45:7–13. doi: 10.7326/0003-4819-45-1-7
Download citation file:
Published: Ann Intern Med. 1956;45(1):7-13.
Cardiology, Heart Failure.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use